ADAR1: a promising new biomarker for esophageal squamous cell carcinoma?

Expert Rev Anticancer Ther. 2014 Aug;14(8):865-8. doi: 10.1586/14737140.2014.928595. Epub 2014 Jun 13.

Abstract

Esophageal Squamous Cell Carcinoma (ESCC) is a heterogeneous tumor with enormous genetic and epigenetic changes. RNA editing is an epigenetic mechanism that serves as an additional layer of 'RNA mutations' in parallel to DNA mutations. The most frequent type of RNA editing, A-to-I (adenosine-to-inosine) editing catalyzed by Adenosine DeAminase that act on RNA (ADARs), modulates RNA transcripts with profound impact on cellular functions. RNA editing dysregulation has been found to be associated with cancers. Our recent study demonstrated that among all the three RNA editing enzymes, only ADAR1 was overexpressed in primary ESCCs compared with matched non-tumor specimens. In this review, we will discuss current views on the involvement of abnormal A-to-I editing in cancer development, more specifically on the ADAR1-mediated editing in ESCC. Although much is not yet learned about the role of ADAR1 in ESCC, ADAR1 may present an attractive option as a new biomarker for ESCC and as a new molecular therapeutic target.

Keywords: ADAR1; RNA editing; biomarker; esophageal squamous cell carcinoma.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenosine Deaminase / genetics*
  • Biomarkers, Tumor / genetics*
  • Carcinoma, Squamous Cell / genetics*
  • Epigenesis, Genetic
  • Esophageal Neoplasms / genetics*
  • Esophageal Squamous Cell Carcinoma
  • Humans
  • Mutation
  • RNA Editing
  • RNA-Binding Proteins / genetics*

Substances

  • Biomarkers, Tumor
  • RNA-Binding Proteins
  • ADAR protein, human
  • Adenosine Deaminase